You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

LASMIDITAN SUCCINATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for lasmiditan succinate and what is the scope of freedom to operate?

Lasmiditan succinate is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lasmiditan succinate has one hundred and eighteen patent family members in forty-four countries.

One supplier is listed for this compound.

Summary for LASMIDITAN SUCCINATE
International Patents:118
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 17
Patent Applications: 1
DailyMed Link:LASMIDITAN SUCCINATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LASMIDITAN SUCCINATE
Generic Entry Date for LASMIDITAN SUCCINATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for LASMIDITAN SUCCINATE
Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
REYVOW Tablets lasmiditan succinate 50 mg and 100 mg 211280 1 2024-01-31

US Patents and Regulatory Information for LASMIDITAN SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LASMIDITAN SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-001 Jan 31, 2020 ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-002 Jan 31, 2020 ⤷  Sign Up ⤷  Sign Up
Eli Lilly And Co REYVOW lasmiditan succinate TABLET;ORAL 211280-003 Dec 18, 2020 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LASMIDITAN SUCCINATE

Country Patent Number Title Estimated Expiration
Taiwan I776175 ⤷  Sign Up
Argentina 039150 PIRIDINOILPIPERIDINAS COMO AGONISTAS DE 5-HT1F ⤷  Sign Up
South Korea 20240027877 2,4,6-트리플루오로-N-[6--피리딘-2-일]-벤즈아미드헤미숙시네이트의 대규모 제조를 위한 방법 및 중간체, 및 2,4,6-트리플루오로-N-[6--피리딘-2-일]-벤즈아미드 아세테이트의 제조 (246--N-[6-1---4---2-]- 246--N-[6-1---4---2-]- Processes and intermediate FOR THE LARGE-SCALE PREPARATION OF 246-trifluoro-N-[6-1-methyl-piperidine-4-carbonyl-pyridin-2-yl]-benzamide Hemisuccinate And preparation of 246-TRIFLUORO-N-[6-1-METHYL-PIPERIDINE-4-CARBONYL-PYRIDIN-2-YL]-BENZAMIDE Acetate) ⤷  Sign Up
Eurasian Patent Organization 007966 ПИРИДИНОИЛПИПЕРИДИНЫ КАК АГОНИСТЫ 5-HT (PYRIDINOYLPIPERIDINES AS 5-HTAGONISTS) ⤷  Sign Up
Costa Rica 20190251 COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT 1F (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.